Noida-based Genient Technologies has appointed Brijesh Singh as its Chief Executive Officer, marking a significant step in the company’s leadership journey as it strengthens its presence in genomics, precision medicine and molecular diagnostics.
Under Singh’s leadership, the company aims to scale next-generation sequencing (NGS) capabilities and deliver clinically relevant molecular solutions across India and neighbouring markets. Genient Technologies is focused on expanding platform-agnostic molecular offerings spanning infectious disease identification, antimicrobial resistance (AMR) testing, precision oncology and epigenetics.
Singh brings over 21 years of experience across the medtech and genomics ecosystem. Over the course of his career, he has held leadership roles at global healthcare and diagnostics organisations, including Roche Diagnostics, Bio-Rad Laboratories, Dr Lal PathLabs, Siemens Healthineers, Fapon Biotech and Fast Track Diagnostics. He has also undertaken strategic roles at Molsera Lifesciences, Radgivning – Law & Advisory India, and Biomolecular Discovery & Solutions.
Previously, Singh served as Director and CEO (India Unit) for a leading Chinese biotech organisation in in-vitro diagnostics (IVD) raw materials and technology, where he drove technology transfers, localised R&D and strengthened manufacturing capabilities in India. He also led and scaled Fast Track Diagnostics Asia as an independent business unit and steered its acquisition by Siemens Healthineers through the NCLT process.
At Genient Technologies, Singh will focus on building accessible, India-relevant genomics aggregation platforms and accelerating diagnostic manufacturing and innovation. The company’s portfolio includes advanced NGS-based drug-resistance solutions and integrates infectious disease assays from ABL Diagnostics, enabling secure and compliant clinical workflows.
Looking ahead, Genient Technologies plans to advance India’s genomics ecosystem through data digitisation, standardisation of epidemiological research and the development of pathogen genome databases. The company aims to strengthen global collaborations while improving healthcare outcomes through scalable and innovation-led molecular diagnostics solutions.